GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (BSP:A1LN34) » Definitions » Shiller PE Ratio

Alnylam Pharmaceuticals (BSP:A1LN34) Shiller PE Ratio : (As of Apr. 29, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Alnylam Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Alnylam Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Alnylam Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Shiller PE Ratio Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alnylam Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alnylam Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alnylam Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Shiller PE Ratio falls into.


;
;

Alnylam Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Alnylam Pharmaceuticals's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Alnylam Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.198/133.1571*133.1571
=-0.198

Current CPI (Dec. 2024) = 133.1571.

Alnylam Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -0.097 99.621 -0.130
201506 -0.132 100.684 -0.175
201509 -0.178 100.392 -0.236
201512 -0.208 99.792 -0.278
201603 -0.224 100.470 -0.297
201606 -0.180 101.688 -0.236
201609 -0.197 101.861 -0.258
201612 -0.221 101.863 -0.289
201703 -0.195 102.862 -0.252
201706 -0.221 103.349 -0.285
201709 -0.210 104.136 -0.269
201712 -0.244 104.011 -0.312
201803 -0.231 105.290 -0.292
201806 -0.307 106.317 -0.385
201809 -0.499 106.507 -0.624
201812 -0.406 105.998 -0.510
201903 -0.332 107.251 -0.412
201906 -0.389 108.070 -0.479
201909 -0.395 108.329 -0.486
201912 -0.507 108.420 -0.623
202003 -0.396 108.902 -0.484
202006 -0.405 108.767 -0.496
202009 -0.589 109.815 -0.714
202012 -0.538 109.897 -0.652
202103 -0.482 111.754 -0.574
202106 -0.405 114.631 -0.470
202109 -0.454 115.734 -0.522
202112 -0.611 117.630 -0.692
202203 -0.498 121.301 -0.547
202206 -0.578 125.017 -0.616
202209 -0.870 125.227 -0.925
202212 -0.441 125.222 -0.469
202303 -0.365 127.348 -0.382
202306 -0.536 128.729 -0.554
202309 0.284 129.860 0.291
202312 -0.269 129.419 -0.277
202403 -0.129 131.776 -0.130
202406 -0.035 132.554 -0.035
202409 -0.241 133.029 -0.241
202412 -0.198 133.157 -0.198

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alnylam Pharmaceuticals  (BSP:A1LN34) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Alnylam Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alnylam Pharmaceuticals Business Description

Traded in Other Exchanges
Address
675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals Headlines

No Headlines